Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab maintenance after radical radiotherapy for stage IV oligometastatic cancer
ChiCTR1900028504Phase 4Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in cancer, bronchial carcinoma and esophageal cancer (3 arms), sponsored by Shanxi Cancer Hospital. Primary endpoint: Objective response rate. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
cancerbronchial carcinomaesophageal cancer
Beyond the preview
Go deeper on ChiCTR1900028504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028504.